Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy

• Published in: Future oncology (London, England) Vol. 17; no. 32; pp. 4343 - 4353
• Main Authors: Hepp, Zsolt, Shah, Sonali N, Liang, Shang-Ying, Tan, Katherine, Balakrishna, Shreya
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.11.2021
• Subjects: Aged; Aged, 80 and over; Bridged-Ring Compounds - therapeutic use; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - mortality; Carcinoma, Transitional Cell - pathology; Female; Humans; Immune Checkpoint Inhibitors - therapeutic use; immune-checkpoint inhibitor; Male; Neoplasm Metastasis; Platinum - therapeutic use; real-world overall survival; real-world progression-free survival; real-world response; Taxoids - therapeutic use; Urologic Neoplasms - drug therapy; Urologic Neoplasms - mortality; Urologic Neoplasms - pathology; urothelial carcinoma; real-world overall survival; urothelial carcinoma; real-world response; immune-checkpoint inhibitor; real-world progression-free survival
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2021-0573

To investigate real-world overall survival (rwOS) and real-world progression-free survival (rwPFS) in locally advanced/metastatic urothelial carcinoma postplatinum and postprogrammed death receptor-1/death ligand 1 inhibitors. Adult patients diagnosed with locally advanced/metastatic urothelial carcinoma from 1 January 2011 to 31 December 2018 and treated with taxane monotherapy or any therapy postplatinum and post-PD-1/L1 inhibitors were included from a nationwide electronic health record-derived oncology database. Median rwOS among 72 patients treated with taxane monotherapy was 7.6 months (95% CI: 5.2–14.4) and rwPFS was 2.9 months (95% CI: 2.4–4.0). Among 208 patients treated with any therapy, median rwOS was 8.9 months (95% CI: 7.3–10.6) and rwPFS was 3.6 months (95% CI: 2.7–4.7). Short duration of rwOS and rwPFS were observed, highlighting the need for effective and safe treatments in this patient population. Few studies have evaluated survival outcomes in patients with advanced urothelial cancer who have disease relapse after chemotherapy and PD-1/L1 inhibitor therapy in clinical practice. In this study, we used electronic health records from a nationwide cancer database to assess survival in adult patients who received further treatment in this setting from 2011 to 2018. Among 72 patients who were treated with taxane monotherapy after chemotherapy and a PD-1/L1 inhibitor, average overall survival was 7.6 months and progression-free survival was 2.9 months. Among 208 patients who were treated with any therapy, average overall survival was 8.9 months and progression-free survival was 3.6 months. These results highlight the need for safer and more effective therapies in patients with advanced urothelial cancer who have disease relapse after chemotherapy and PD-1/L1 inhibitor therapy. In patients with advanced urothelial carcinoma who progressed on platinum and PD-1/L1 inhibitor therapy, median real-world OS and PFS on subsequent treatment were only 7.6–8.9 and 2.9–3.6 months.